MedWatch

Another Genmab drug from Janssen receives breakthrough therapy designation

The US FDA has given breakthrough therapy status to the cancer drug teclistamab which is based on Genmab's Duobody platform.

Photo: Joost Melis / Genmab / PR

Shortly after Janssen secured approval from the US Food and Drug Administration (FDA) for the Genmab-developed lung cancer drug Rybrevant, the pharmaceutical company has taken a crucial step with another drug from Genmab's Duobody platform.

In a press release, Janssen reports that teclistamab has received breakthrough therapy designation from the FDA.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs